Tag: heart failure

1. In the pre-COVID-19 analysis, hemodynamic monitoring reduced hospitalization and all-cause mortality rates. 2. After the COVID-19 pandemic started, hospitalization of heart failure patients was reduced and there were no appreciable differences between the control and hemodynamic monitoring group. Evidence Rating Level: 1 (Excellent) Study Rundown: Worsening hemodynamic congestion is a major...
1. Transthyretin amyloid cardiomyopathy was present in a substantial number of patients with heart failure with preserved ejection fraction and ventricular wall thickening in a community-based cohort, especially among older men. 2. With effective therapy available to treat transthyretin amyloid cardiomyopathy, targeted systematic evaluation in patients with heart failure with...
1. Sotagliflozin treatment was shown to increase the days-alive-and-out-of-hospital compared to placebo in patients with type 2 diabetes and heart failure. 2. Sotagliflozin treatment was shown to significantly decrease the rate of days dead compared to the placebo treatment. Evidence Rating Level: 1 (Excellent) Study Rundown: Sodium-glucose cotransporter 2 (SGLT2) inhibitors have...
1. In this cohort study, 91% of patients with preserved ejection fraction heart failure had evidence of epicardial coronary artery disease and/or coronary microvascular dysfunction. 2. Due to the high prevalence of these conditions, coronary artery disease and coronary microvascular dysfunction may be unrecognized and underdiagnosed in patients hospitalized with...
1. Hypertension, diabetes, smoking, atrial fibrillation, and previous myocardial infarction were associated with a higher risk of incident heart failure in younger adults (<55 years) compared to elderly participants (≥75 years). 2. There were no interactions between age and body-mass index or glomerular filtration rate with respect to the incidence...
1. Pre-term birth was associated with significantly increased risk of adult-onset heart failure, particularly among those 18 to 43 years of age. Evidence Rating Level: 2 (Good) Preterm birth is a known risk factor for early-life heart failure (HF). However, less is known about its association with adult-onset HF. This Swedish...
1. Across all age groups at the time of diagnosis, younger gestational ages were associated with an increased risk of developing heart failure later in life. Evidence Rating Level: 2 (Good) Study Rundown: Preterm birth is an extremely common condition affecting mothers worldwide. The association between preterm birth and various cardiac...
1. In both obese and non-obese patients, NT-proBNP level <1000pg/mL during treatment showed favourable prognostic implications in heart failure with reduced ejection fraction. Evidence Rating Level: 2 (Good) While obesity itself is a major risk factor for developing heart failure, overweight and obese patients have been reported to have paradoxically better...
1. Risk factors, such as hypertension, diabetes, smoking and history of myocardial infarction, were associated with a higher risk of developing heart failure in younger populations compared to older populations. 2. Population-attributable risk of heart failure was better explained by traditional risk factors in younger than in elderly patients. Evidence Rating...
1. Patients who received omecamtiv mecarbil had slightly fewer systolic heart failure exacerbations compared to those who received placebo. 2. Serious adverse events occurred equally frequently in both groups. Evidence Rating Level: 1 (Excellent) Study Rundown: At present, no medications that directly stimulate systolic function have been shown to improve health outcomes...